Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hermogenyx shares soar on new partnership with Prevail Partners

Mon 18 Sep 2023 13:00

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Investment fund Prevail Partners purchased 11.1m shares at a price of 7.5 US cents a share (around 6p a share), representing a 240% premium to Hemogenyx's closing price on Friday.

It has entered into a master service and technology agreement (MSTA) with Prevail Partners' affiliate company, Prevail InfoWorks, whereby the latter will provide clinical services for Hemogenyx's upcoming Phase I study of its anti-FLT3 CAR-T cell treatment for people suffering with relapsed/refractory acute myeloid leukaemia (AML).

The stock was up 26% at 2.34p by 1401.

Hemogenyx said Prevail Partners' investment "will in large part defray the payment made by the company for the first stage of the work being undertaken by InfoWorks under the MSTA".

InfoWorks will provide clinical site coordination, project management, data management, clinical monitoring, and safety management services.

AML is the most common type of acute leukaemia in adults and has a five-year survival rate of less than 30%. It it currently treated using chemotherapy, but Hemogenyx's CAR-T cell treatment a "potentially more benign and effective form of therapy". CAR-T therapy is a new type of treatment in which a patient's own immune cells are modified to recognise and kill cancer cells.

"Prevail Partners' strategic investment in the company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study," said Hemogenyx's chief executive and co-founder Vladislav Sandler.

Share this article

Related Sharecast Articles

Mon 07 Sep 2026 08:45
The Works raises FY profit guidance as strong early‑year trading boosts momentum
(Sharecast News) - Stationery retailer The Works said on Monday that trading had continued to build momentum in the opening weeks of its new financial year, prompting it to lift profit expectations after a strong start.
Fri 24 Jul 2026 09:11
Wise to reapply for US trust-bank charter after OCC rejection
(Sharecast News) - Fintech group Wise said on Friday that the US Office of the Comptroller of the Currency had denied its application for a national trust bank charter, noting the decision relates to issues in its original submission more than a year ago.
Mon 29 Jun 2026 14:00
Smiths News inks distribution contract with Associated Newspapers
(Sharecast News) - Print media distributor Smiths News has secured a new long‑term distribution contract with Associated Newspapers, publisher of the Daily Mail, The Mail on Sunday and i.
Thu 04 Jun 2026 08:30
S4 Capital flags tough trading amid volatile macro conditions
(Sharecast News) - Digital advertising and marketing firm S4 Capital said on Thursday that trading through 2025 had continued to reflect volatile macro conditions, with tariff negotiations and geopolitical risks keeping clients cautious.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026